Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PPD Establishes Biotherapeutics JV | Contract Pharma

What are you searching for?

Sign in
Breaking News

PPD Establishes Biotherapeutics JV

PPD, Inc. has established a joint venture with Taijitu Biologics Ltd. (TBL), named BioDuro Biologics, to discover novel biotherapeutics.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PPD, Inc. has established a joint venture with Taijitu Biologics Ltd. (TBL), named BioDuro Biologics, to discover novel biotherapeutics. BioDuro Biologics aims to develop and commercialize an innovative technology platform for the discovery of first- and best-in-class monoclonal antibody therapies in collaboration with MAB Discovery GmbH in Munich, Germany. The JV will then provide drug discovery services based on this technology platform to global biopharma companies.

Based in Singapore, BioDuro Biologics allows PPD to take advantage of the growth and success of biotherapeutics and creates opportunities for BioDuro, PPD’s drug discovery business, to provide additional services for antibodies discovered using the new technology platform. PPD owns a majority stake in the JV and has committed to invest $25 million.

“Developing a best-in-class, innovative technology platform for the discovery of monoclonal antibodies allows us to continue to deliver highly valued discovery services for our clients in the growing area of large molecule drug discovery,” said Lee Babiss, Ph.D., executive vice president of global laboratory services for PPD. “As PPD continues to invest in drug discovery, we are well-positioned to deliver high quality, innovative drug discovery technologies and expertise that advance our clients’ compounds more quickly and cost efficiently.”

Stephan Fischer, Ph.D., founder and co-owner of TBL and MAB Discovery GmbH, will serve as a member of BioDuro Biologics’ board of directors and will lead the development of the technology platform, which is expected to be completed by mid-2011.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics